4M Therapeutics, Inc., Enters Into Strategic Partnership with Vala Sciences, Inc., to Advance the 4MTx Pipeline
Alexandra-Sophia C. Piliotis
4M Therapeutics, Inc.
4M Therapeutics, Inc., Enters Into Strategic Partnership with Vala Sciences, Inc., to Advance the 4MTx Pipeline
[Skillman, NJ & San Diego, CA]: 4M Therapeutics, Inc., (4MTx) today announced a new partnership with Vala Sciences Inc. (Vala). This partnership will leverage Vala’s expert services via their breakthrough kinetic high-content screening technology and toolset to advance 4MTx’s innovative pipeline.
“I am excited to partner with Vala and work with Jeff Price again,” says Stephen J. Haggarty, Ph.D., Scientific Founder at 4MTx. “Jeff and I worked together previously conducting NIH funded research to advance the understanding of pathways to target for treating of bipolar disorder. It is amazing to have this innovative team that has worked with me coming back to advance the 4M Therapeutics pipeline.”
“I have known Stephen Haggarty for many years, and we have published together in the Proceedings of the National Academy of Sciences,” says Jeffrey H. Price, M.D., Ph.D., CEO, Founder, and President at Vala. “Stephen’s expertise in neuroscience and drug discovery is a formidable combination. We are honored to help advance an innovative pipeline derived from Stephen’s and his colleague’s human stem cell-based screens and discovery of neuroplasticity mechanisms that have the potential for treating multiple neuropsychiatric disorders.”
The partnership of 4MTx and Vala Sciences builds upon on this previously successful collaboration to produce cutting-edge work.
About 4MTx: 4M Therapeutics Inc. is a startup biotech company based on the principle that the study of human brain cells represents an important advance in neuroscience discovery. 4MTx has developed a pipeline of small molecules by studying their effects on brain cells derived from human induced pluripotent stem cells. The initial focus is bipolar disorder and Alzheimer's disease, conditions where targeted drug discovery can support and improve neuroplasticity and neurogenesis. The scientific founders are world-leaders in neurobiology, chemistry, and the pharmacology of neuroplasticity. For more information, please visit www.4mtx.net and engage with us on LinkedIn.
About Vala: Vala Sciences, Inc., is a biotechnology company that performs proprietary phenotypic Kinetic Image Cytometry® (KIC®, a superset of high content screening) to achieve unrivaled in vitro prediction of human clinical responses to drug compounds. Vala leverages its expertise in cardiac and neural biology, cell imaging, data analysis, and assay development to reduce clinical failures of drug candidates. Vala’s toolset, which includes the most advanced high throughput functional disease models of human iPSC-derived heart, brain, and muscle tissues, delivers the highest predictivity of human responses. For more information on Vala Sciences Inc., please visit valasciences.com and engage with us on LinkedIn.